ArticleThe Prostate2015
Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.
Article in The Prostate, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 79 citations in OpenAlex.
- The periphery of pituitary macroadenoma expressed higher invasive capability: the importance of clinical implication.Discover oncology · 2025Article
- Review
- An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC.International journal of molecular sciences · 2023Article
- The role of tumor model in magnetic targeting of magnetosomes and ultramagnetic liposomes.Scientific reports · 2023Article
- Deep learning-based automated pipeline for blood vessel detection and distribution analysis in multiplexed prostate cancer images.Frontiers in bioinformatics · 2023Article
- TNF Signaling Is Required for Castration-Induced Vascular Damage Preceding Prostate Cancer Regression.Cancers · 2022Article
- Article
- CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Characterization of the Tumor Microenvironment and the Biological Processes with a Role in Prostatic Tumorigenesis.Biomedicines · 2022Article
- Computed tomography perfusion imaging evaluation of angiogenesis in patients with pancreatic adenocarcinoma.World journal of clinical cases · 2022Article
- Expression and clinical significance of CD31, CD34, and CD105 in pulmonary ground glass nodules with different vascular manifestations on CT.Frontiers in oncology · 2022Article
- Research on the prognosis of different types of microvessels in bladder transitional cell carcinoma.World journal of clinical cases · 2021Article
- Endoglin Expression and Microvessel Density as Prognostic Factors in Pediatric Rhabdomyosarcoma.Journal of clinical medicine · 2021Article
- Predictive value of microvessel features for the clinical response to neoadjuvant chemotherapy in cervical squamous carcinoma and the associations with prognosis.Translational cancer research · 2021Article
- Correlation between peripheral blood neutrophil-lymphocyte ratio and CD34 expression in prostate cancer.BMC cancer · 2020Article
- The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.PloS one · 2020Article
- Prognostic value of stem cell markers in esophageal and esophagogastric junction cancer: a meta-analysis.Journal of Cancer · 2020Article
- Article
- The effectiveness and safety of X-PDT for cutaneous squamous cell carcinoma and melanoma.Nanomedicine (London, England) · 2019Article
- Cartilage oligomeric matrix protein in patients with osteoarthritis is independently associated with metastatic disease in prostate cancer.Oncotarget · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant hormonal therapy (NHT) is performed to improve the outcome in organ-confined prostate cancer. However, there is little information regarding the relationship between angiogenesis and NHT. The aim of this study was to identify a suitable method to evaluate the angiogenic status of tissue, and to determine the prognostic value of this method for biochemical recurrence in patients who had undergone radical prostatectomy after NHT.
methodsWe analyzed 108 formalin-fixed specimens from patients treated by radical prostatectomy. NHT was administered in 48 patients (52.9%) and 60 patients who had a similar Gleason score and pT stage were selected as a non-NHT treated control group. Microvessel density (MVD) was measured using anti-CD31, anti-CD34, and anti-CD105 antibodies. The expressions of vascular endothelial growth factor (VEGF)-A and thrombospondin (TSP)-1 were also evaluated by immunohistochemistry. The prognostic value of CD31-, CD34-, and CD105-MVD for biochemical recurrence was investigated.
resultsThe mean/SD of CD105-MVD in the NHT group (13.3/4.7) was significantly (P < 0.001) lower than that in the non-NHT group (125.8/7.3). In the NHT group, CD105-MVD was associated with pT stage and it was positively correlated with VEGF-A expression (r = 0.56, P < 0.001) and negatively correlated with TSP-1 expression (r = 0.42, P = 0.003). CD105-MVD was identified as a significant predictor of biochemical recurrence (BCR) in patients treated with NHT (log rank test, P < 0.001). Although CD31- and CD34-MVD were significantly associated with pT stage or Gleason score in non-NHT group, they were not associated with pathological features and BCR in NHT group.
conclusionsOur results indicate that CD105-MVD reflects the angiogenic conditions in prostate cancer tissues treated with NHT. CD105-MVD was also identified as a significant and independent predictor of biochemical recurrence in prostate cancer patients who underwent radical prostatectomy with NHT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.